Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Core Insights - Aprea Therapeutics has initiated a Phase 1/2a clinical trial for its experimental drug ATRN-119, with the first patient dosed at a new twice-daily regimen of 550 mg [1][2] - The trial aims to evaluate ATRN-119 as a monotherapy for patients with advanced solid tumors that have mutations in DNA damage response-related genes [2][5] - The twice-daily dosing is expected to enhance the drug's efficacy and optimize therapeutic levels, potentially leading to better clinical outcomes and a faster path to regulatory approval [3][4] Company Overview - Aprea Therapeutics is focused on developing innovative therapies for cancers with specific genetic alterations, aiming to minimize damage to healthy cells [1][5] - ATRN-119 is a first-in-class macrocyclic ATR inhibitor designed for patients with mutations in DNA damage response-related genes, addressing a significant unmet medical need [5][7] - The company is committed to refining its clinical approach based on scientific evidence, which may enhance shareholder value and create partnership opportunities for commercialization [4][6] Clinical Trial Details - The ABOYA-119 trial has been amended to allow for twice-daily dosing, which is expected to improve the drug's pharmacokinetics and pharmacodynamics [2][3] - The primary endpoint of the trial is to assess the tolerability and pharmacokinetics of ATRN-119, with results anticipated in the second half of 2025 [4][3] - The trial will continue to explore both once-daily and twice-daily dosing schedules independently [4]